Cabio Biotech Wuhan Co Ltd
SSE:688089
Income Statement
Earnings Waterfall
Cabio Biotech Wuhan Co Ltd
Revenue
|
485m
CNY
|
Cost of Revenue
|
-297.1m
CNY
|
Gross Profit
|
187.9m
CNY
|
Operating Expenses
|
-156.7m
CNY
|
Operating Income
|
31.2m
CNY
|
Other Expenses
|
15.7m
CNY
|
Net Income
|
46.9m
CNY
|
Income Statement
Cabio Biotech Wuhan Co Ltd
Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue |
348
N/A
|
359
+3%
|
374
+4%
|
433
+16%
|
446
+3%
|
461
+3%
|
485
+5%
|
|
Gross Profit | ||||||||
Cost of Revenue |
(182)
|
(200)
|
(216)
|
(253)
|
(270)
|
(280)
|
(297)
|
|
Gross Profit |
166
N/A
|
159
-4%
|
158
0%
|
180
+14%
|
175
-3%
|
181
+3%
|
188
+4%
|
|
Operating Income | ||||||||
Operating Expenses |
(75)
|
(76)
|
(85)
|
(109)
|
(144)
|
(155)
|
(157)
|
|
Selling, General & Administrative |
(49)
|
(55)
|
(58)
|
(82)
|
(82)
|
(85)
|
(88)
|
|
Research & Development |
(31)
|
(34)
|
(40)
|
(30)
|
(34)
|
(35)
|
(34)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
|
Other Operating Expenses |
6
|
13
|
13
|
8
|
(28)
|
(34)
|
(34)
|
|
Operating Income |
91
N/A
|
83
-9%
|
73
-12%
|
71
-3%
|
32
-55%
|
26
-18%
|
31
+20%
|
|
Pre-Tax Income | ||||||||
Interest Income Expense |
11
|
18
|
23
|
13
|
11
|
8
|
(1)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
(33)
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
(0)
|
0
|
(1)
|
0
|
0
|
0
|
|
Total Other Income |
34
|
27
|
24
|
28
|
27
|
26
|
26
|
|
Pre-Tax Income |
136
N/A
|
127
-7%
|
120
-6%
|
78
-35%
|
69
-12%
|
60
-13%
|
56
-7%
|
|
Net Income | ||||||||
Tax Provision |
(18)
|
(19)
|
(17)
|
(17)
|
(16)
|
(14)
|
(12)
|
|
Income from Continuing Operations |
118
|
108
|
102
|
62
|
53
|
46
|
43
|
|
Income to Minority Interest |
(0)
|
3
|
3
|
3
|
2
|
3
|
4
|
|
Net Income (Common) |
118
N/A
|
111
-6%
|
105
-5%
|
64
-39%
|
55
-14%
|
49
-11%
|
47
-5%
|
|
EPS (Diluted) |
0.98
N/A
|
0.93
-5%
|
0.62
-33%
|
0.38
-39%
|
0.33
-13%
|
0.29
-12%
|
0.28
-3%
|